RxDoctor Payments Data

Samantha Dimeo

Family · Cincinnati, OHNPI 1841840071

Payments from drug & device makers

$3,034in general payments, 2019–2025

Across 104 payments — averaging $29.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$726
  • Biohaven Pharmaceuticals, Inc.$154
  • Biogen$129
  • Neurocrine Biosciences, Inc.$119
  • Argenx US, Inc.$109
  • plus $388 from 11 others

What the payments were for

  • Consulting fees$68523%
  • Food & beverage$2,34977%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,034 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$46,252
Medicare patients
124
Services billed
12,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant33$35,573
LamictalLamotrigine16$19,569
UbrelvyUbrogepant14$16,047
Pyridostigmine Bromide54$6,725
Levetiracetam186$5,373
Lacosamide17$3,940
Gabapentin273$3,074
Oxcarbazepine51$2,457
Donepezil Hcl217$1,952
Divalproex Sodium25$1,930
Carbidopa-LevodopaCarbidopa/Levodopa112$1,678
Memantine Hcl84$1,567
Primidone44$1,263
Propranolol Hcl ErPropranolol Hcl26$896
Pregabalin62$848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$1,409$51,62047 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$30$6,72554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →